GL1X · GenesisL1 explorer

Research workbench

In cellulo crystal structure of PAK4 in complex with inka

Analyse In cellulo crystal structure of PAK4 in complex with inka in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4XBR
Type
protein
Length
316 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Protein FAM212A,SERINE/THREONINE-protein kinase pak 4
EC
2.7.11.1
UniProt
Q96EL1, O96013
Ligands
ATP, MG
Pockets
3 · best druggability 0.64

Structure

x-ray diffraction · 1 distinct chain · 40% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AProtein FAM212A,SERINE/THREONINE-protein kinase pak 4 (EC 2.7.11.1)protein31640% helix, 18% strandQ96EL1, O96013

Ligands and binding sites

  • ATP · Adenosine-5'-triphosphate · ligand · chains A
  • MG · Magnesium ion · metal · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13000.640.8131ATP, MG
2610.380.7916empty
3580.300.7514empty

Modifications

Observed in the structure: 1 modified (phosphorylation).

Compared structures

  • 4XBR · In cellulo Crystal Structure of PAK4 in complex with Inka · the same entry in another collection · chain A against A, TM-score 1.00
  • O96013 · AlphaFold monomer V2.0 prediction for SERINE/THREONINE-protein kinase pak 4 (O96013) · a predicted model of the same protein · chain A against A, TM-score 0.92
  • Q96EL1 · AlphaFold monomer V2.0 prediction for PAK4-inhibitor INKA1 (Q96EL1) · a predicted model of the same protein · chain A against A, TM-score 0.17

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.